Getting closer to data
Intec is moving closer to data from its clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP). The AP is specifically designed to improve gastroretention as a controlled release solution for difficult-to-formulate drugs. The lead programme is a Phase III study of AP-CDLD (carbidopa and levodopa) in Parkinson’s, which is expected to be completely enrolled in Q417. It is also in a Phase I clinical study (targeting Q317 completion) of AP-CDB/THC (cannabidiol and tetrahydrocannabinol) for the treatment of pain and is seeking a development partner for is sleep aid, AP-ZP (zaleplon).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.